Article: Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma.

Interim Phase 1 Data Presented at International Conference on Malignant Lymphomas Shows Dose Dependent Single Agent Activity

BETHESDA, Md., June 5 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented an update of an ongoing phase 1 clinical trial for its BiTE(R) antibody blinatumomab (MT103/MEDI-538) at the 10th International Conference on Malignant Lymphomas (ICML) in Lugano, Switzerland. The new data(1) with the CD19-specific BiTE antibody show that all seven patients in the highest dose cohort tested so far (0.06 ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!